KRAS and colorectal carcinoma: In our retrospective quality assessment analysis of the NGS assay, KRAS mutations of less than 10% mutant alleles were observed in 5% of KRAS-mutated CRC specimens [31] and in 14% of KRAS-mutated lung cancer specimens (data not shown).